4 International Journal of Hypertension one a day in women (10 g alcohol)). In hypertensive subjects, consumption beyond these levels would be unwise [37]. The reduction of blood pressure is always the compre- hensive eﬀect of the lifestyle interventions in the manage- ment of prehypertension. The main 6-month results from the PREMIER trial showed that comprehensive behavioral intervention programs improved blood pressure [38]. target organ damage, and cardiovascular-related morbidity and mortality [43]. Despite progress in recent years in the prevention, detection, and treatment of Prehypertension, it remains an important public health challenge that adopts appropriate treatments to prehypertensive group in diﬀerent degrees eﬀectively. The reasonable evaluation and appropri- ate intervention of prehypertensive need further study. 3.8. Pharmacological Treatments. Whether people without diabetes or chronic kidney disease (CKD) should be given pharmacological treatments or not is still on discussion [39]. The pharmacological treatments could be used on condition that lifestyle modiﬁcation trial fails to reduce blood pressure to 130/80 mmHg or less according to the JNC-7 guidelines for prehypertension without diabetes or chronic kidney disease (CKD) [1]. The trial of TROPHY study evaluated the eﬀect of the angiotensin II receptor antagonist candesartan cilexetil on the prevention of tran- sition from prehypertension to stage 1 hypertension [40]. Participants were randomly assigned to receive two years of candesartan (Atacand, AstraZeneca) or placebo, followed by two years of placebo for all. When a participant reached the study end point of stage 1 hypertension, treatment with antihypertensive agents was initiated. Both the candesartan group and the placebo group were instructed to make changes in lifestyle to reduce blood pressure throughout the trial. Over a period of four years, stage 1 hypertension developed in nearly two thirds of patients with untreated prehypertension, and the prehypertension treated with can- desartan appeared to be well tolerated and reduced the risk of incident hypertension during the study period. Another study evaluated the impact of bovine casein hydrolysate (c12 Peptide) on prehypertension. After four weeks, repeated daily intake of 3.8 g C12 peptide, the systolic, and diastolic BP reduced signiﬁcantly by about 10 mmHg and 7 mmHg, respectively [41]. The drug intervention in patients with prehypertension is therefore appealing. In the absence of higher baseline risk, the absolute beneﬁt of treatment is presumably small and was not demonstrated to date. These individuals could be candidates to treatment with the aim to prevent the development of full hypertension. The long- lasting eﬀectiveness of nondrug therapies is low outside the controlled conditions of randomized clinical trials, and there is evidences that the use of BP-lowering drugs reduces the incidence of hypertension in individuals with prehypertension by more than 60%. Clinical trials testing the eﬃcacy and safety of BP agents to prevent hypertension in a population-based perspective are required. In the meantime, it is worthy to present the option to start low doses of BP agents for individuals with prehypertension without comorbidities who do not respond to the prescription of lifestyle modiﬁcation [42]. 4. Conclusions The category of “prehypertension” increases the awareness of the high risk group of hypertension. Individuals with Prehy- pertension have an increased risk of full-blown hypertension, References [1] A. V. Chobanian, G. L. Bakris, H. R. Black et al., “Sev- enth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure,” Hypertension, vol. 42, no. 6, pp. 1206–1252, 2003. [2] R. S. Vasan, M. G. Larson, E. P. Leip, W. B. Kannel, and D. Levy, “Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study,” The Lancet, vol. 358, no. 9294, pp. 1682–1686, 2001. [3] H. A. Liszka, A. G. Mainous, D. E. King, C. J. Everett, and B. M. Egan, “Prehypertension and cardiovascular morbidity,” Annals of Family Medicine, vol. 3, no. 4, pp. 294–299, 2005. [4] K. C. Ferdinand and R. S. Pacini, “New evidence conﬁrms risks associated with prehypertension and beneﬁts of ther- apeutic lifestyle changes in management,” Journal of the Cardiometabolic Syndrome, vol. 2, no. 4, pp. 302–304, 2007. [5] Y. Wang and Q. J. Wang, “The prevalence of prehypertension and hypertension among US Adults According to the New Joint National Committee Guidelines: new challenges of the old problem,” Archives of Internal Medicine, vol. 164, no. 19, pp. 2126–2134, 2004. [6] A. K. Gupta, M. McGlone, F. L. Greenway, and W. D. Johnson, “Prehypertension in disease-free adults: a marker for an adverse cardiometabolic risk proﬁle,” Hypertension Research, vol. 33, no. 9, pp. 905–910, 2010. [7] C. Chrysohoou, C. Pitsavos, D. B. Panagiotakos, J. Skoumas, and C. Stefanadis, “Association between prehypertension status and inﬂammatory markers related to atherosclerotic disease: the ATTICA Study,” American Journal of Hypertension, vol. 17, no. 7, pp. 568–573, 2004. [8] K. M. Choi, H. S. Park, J. H. Han et al., “Prevalence of prehypertension and hypertension in a Korean population: Korean National Health and Nutrition Survey 2001,” Journal of Hypertension, vol. 24, no. 8, pp. 1515–1521, 2006. [9] Y. Ishikawa, J. Ishikawa, S. Ishikawa et al., “Prevalence and determinants of prehypertension in a Japanese general pop- ulation: the Jichi Medical School cohort study,” Hypertension Research, vol. 31, no. 7, pp. 1323–1330, 2008. [10] J. W. Sit, L. Sijian, E. M. Wong et al., “Prevalence and risk factors associated with prehypertension: identiﬁcation of foci for primary prevention of hypertension,” Journal of Cardiovascular Nursing, vol. 25, no. 6, pp. 461–469, 2010. [11] J. Yang, F. Lu, C. Zhang et al., “Prevalence of prehypertension and hypertension in a Chinese rural area from 1991 to 2007,” Hypertension Research, vol. 33, no. 4, pp. 331–337, 2010. [12] K. J. Greenland, J. B. Croft, and G. A. Mensah, “Prevalence of heart disease and stroke risk factors in persons with prehypertension in the United States, 1999–2000,” Archives of Internal Medicine, vol. 164, no. 19, pp. 2113–2118, 2004. [13] A. R. Mainous, C. J. Everett, H. Liszka, D. E. King, and B. M. Egan, “Prehypertension and mortality in a nationally representative cohort,” American Journal of Cardiology, vol. 94, no. 12, pp. 1496–1500, 2004.